GAITHERSBURG, Md.--(BUSINESS WIRE)--MaxCyte, Inc., the pioneer in scalable, high performance transient transfection systems, is hosting an educational webinar entitled “Large Scale, CHO Transient Transfection and Rapid Generation of Stable Clones: >1 Gram/Liter Antibody Titers Within 2 Weeks and High Yield Stable Clones in Under 8 Weeks” on Wednesday, June 19, 2013, from 11:00 AM – 12:00 PM EDT.
This scientific webinar will focus on antibody production via CHO transient transfection, a major industry challenge solved by the application of MaxCyte’s proprietary flow electroporation, as well as the unique ability to use this single transfection platform to rapidly produce high-yield stable cell lines. A key portion of the webinar will be a case study presented by Dr. Hua Tu, CEO of LakePharma, Inc., a service provider for the engineering and production of recombinant proteins and antibodies. Dr. Tu will present data generated during the evaluation and implementation of MaxCyte electroporation for antibody production at LakePharma, highlighting the superior performance of MaxCyte transfection over chemical means of transfection including PEI.
“The MaxCyte STX has dramatically improved our antibody production capabilities by seven times over our previous transfection methods,” says Dr. Tu, CEO of LakePharma, Inc. “As a provider of recombinant protein services, this has had a significant impact at LakePharma. I look forward to sharing how MaxCyte’s technology has enhanced our protein production capabilities.”
In addition to Dr. Tu’s presentation, Dr. Peer Heine, Applications Scientist at MaxCyte, will discuss the optimization of MaxCyte electroporation and post transfection culture conditions enabling antibody titers >1gram/liter and the use of MaxCyte transfection for the rapid production of stable cell lines. Dr. Heine will share data demonstrating the reproducibility, scalability, and general protein production capabilities of the MaxCyte STX® Scalable Transfection System and the MaxCyte VLX® Large Scale Transfection System.
“MaxCyte’s platform has led to the breakthrough ability to produce gram scale quantities of antibodies in CHO cells using transient transfection, and can also be used to rapidly produce recombinant proteins in other relevant cell types such as HEK, NS0, Vero, CAP-T™ and insect cells,” says Dr. Karen Donato, EVP of Global Business Development and Marketing at MaxCyte. “We are delighted that Dr. Tu is participating in this webinar to present real-world data and the positive impact of MaxCyte’s technology at LakePharma.”
Interested participants can find out more information and register for the webinar on MaxCyte’s web site: http://www.maxcyte.com/MaxCyte-Company/MaxCyte-Upcoming-Webinar-June-2013.html
MaxCyte specializes in high performance cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Drawing on its cell therapy expertise, MaxCyte has designed a portfolio of products including the MaxCyte STX® Scalable Transfection System and MaxCyte VLX® Large Scale Transfection System, ideal tools for use in drug discovery research, screening, and protein production environments. These products enable the rapid development and consistent production of (co)transfected primary cells, stem cells, and cell lines for protein and antibody production and for cell‐based assays, with comparable results and Seamless Scalability™ from the bench to HTS, pilot, and production scale.
For more information, http://www.maxcyte.com.